Cite
Glucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients.
MLA
Ali, Sadaf, et al. “Glucagon‐like Peptide‐1 Analogues in Monogenic Syndromic Obesity: Real‐world Data from a Large Cohort of Alström Syndrome Patients.” Diabetes, Obesity & Metabolism, vol. 26, no. 3, Mar. 2024, pp. 989–96. EBSCOhost, https://doi.org/10.1111/dom.15398.
APA
Ali, S., Baig, S., Wanninayake, S., da Silva Xavier, G., Dawson, C., Paisey, R., & Geberhiwot, T. (2024). Glucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients. Diabetes, Obesity & Metabolism, 26(3), 989–996. https://doi.org/10.1111/dom.15398
Chicago
Ali, Sadaf, Shanat Baig, Subadra Wanninayake, Gabriela da Silva Xavier, Charlotte Dawson, Richard Paisey, and Tarekegn Geberhiwot. 2024. “Glucagon‐like Peptide‐1 Analogues in Monogenic Syndromic Obesity: Real‐world Data from a Large Cohort of Alström Syndrome Patients.” Diabetes, Obesity & Metabolism 26 (3): 989–96. doi:10.1111/dom.15398.